PortfoliosLab logoPortfoliosLab logo
KPTI vs. ENTA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

KPTI vs. ENTA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Karyopharm Therapeutics Inc. (KPTI) and Enanta Pharmaceuticals, Inc. (ENTA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, KPTI achieves a 25.41% return, which is significantly higher than ENTA's -23.72% return. Over the past 10 years, KPTI has underperformed ENTA with an annualized return of -23.74%, while ENTA has yielded a comparatively higher -7.21% annualized return.


KPTI

1D
-6.01%
1M
5.25%
YTD
25.41%
6M
72.20%
1Y
124.03%
3Y*
-35.19%
5Y*
-41.84%
10Y*
-23.74%

ENTA

1D
-5.05%
1M
-16.17%
YTD
-23.72%
6M
-13.83%
1Y
91.26%
3Y*
-22.59%
5Y*
-23.99%
10Y*
-7.21%
*Multi-year figures are annualized to reflect compound growth (CAGR)

KPTI vs. ENTA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
KPTI
Karyopharm Therapeutics Inc.
25.41%-27.45%-21.82%-74.56%-47.12%-58.46%-19.25%104.59%-2.40%2.13%
ENTA
Enanta Pharmaceuticals, Inc.
-23.72%174.26%-38.89%-79.77%-37.79%77.62%-31.85%-12.78%20.71%75.16%

Correlation

The correlation between KPTI and ENTA is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.21

Correlation (3Y)
Calculated over the trailing 3-year period

0.29

Correlation (5Y)
Calculated over the trailing 5-year period

0.36

Correlation (10Y)
Calculated over the trailing 10-year period

0.38

Correlation (All Time)
Calculated using the full available price history since Nov 7, 2013

0.37

The correlation between KPTI and ENTA shifts across timeframes, from 0.21 (1 year) to 0.38 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

KPTI:

$228.12M

ENTA:

$347.57M

EPS

KPTI:

-$13.00

ENTA:

-$2.67

PS Ratio

KPTI:

0.92

ENTA:

4.04

Total Revenue (TTM)

KPTI:

$151.12M

ENTA:

$69.21M

Gross Profit (TTM)

KPTI:

$145.13M

ENTA:

$33.44M

EBITDA (TTM)

KPTI:

-$93.05M

ENTA:

-$61.85M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

KPTI vs. ENTA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KPTI
KPTI Risk / Return Rank: 7777
Overall Rank
KPTI Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
KPTI Sortino Ratio Rank: 7878
Sortino Ratio Rank
KPTI Omega Ratio Rank: 7474
Omega Ratio Rank
KPTI Calmar Ratio Rank: 7878
Calmar Ratio Rank
KPTI Martin Ratio Rank: 7878
Martin Ratio Rank

ENTA
ENTA Risk / Return Rank: 7878
Overall Rank
ENTA Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
ENTA Sortino Ratio Rank: 8282
Sortino Ratio Rank
ENTA Omega Ratio Rank: 8181
Omega Ratio Rank
ENTA Calmar Ratio Rank: 8383
Calmar Ratio Rank
ENTA Martin Ratio Rank: 7777
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KPTI vs. ENTA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and Enanta Pharmaceuticals, Inc. (ENTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


KPTIENTADifference

Sharpe ratio

Return per unit of total volatility

1.33

0.83

+0.49

Sortino ratio

Return per unit of downside risk

2.29

2.49

-0.21

Omega ratio

Gain probability vs. loss probability

1.26

1.32

-0.06

Calmar ratio

Return relative to maximum drawdown

2.48

3.23

-0.75

Martin ratio

Return relative to average drawdown

6.15

5.96

+0.19

KPTI vs. ENTA - Sharpe Ratio Comparison

The current KPTI Sharpe Ratio is 1.33, which is higher than the ENTA Sharpe Ratio of 0.83. The chart below compares the historical Sharpe Ratios of KPTI and ENTA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


KPTIENTADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.33

0.83

+0.49

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.44

-0.33

-0.11

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.28

-0.12

-0.16

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.26

-0.04

-0.22

Drawdowns

KPTI vs. ENTA - Drawdown Comparison

The maximum KPTI drawdown since its inception was -99.50%, roughly equal to the maximum ENTA drawdown of -96.63%. Use the drawdown chart below to compare losses from any high point for KPTI and ENTA.


Loading charts...

Drawdown Indicators


KPTIENTADifference

Max Drawdown

Largest peak-to-trough decline

-99.50%

-96.63%

-2.87%

Max Drawdown (1Y)

Largest decline over 1 year

-48.36%

-31.86%

-16.50%

Max Drawdown (3Y)

Largest decline over 3 years

-90.08%

-83.80%

-6.28%

Max Drawdown (5Y)

Largest decline over 5 years

-98.36%

-95.62%

-2.74%

Max Drawdown (10Y)

Largest decline over 10 years

-99.15%

-96.63%

-2.52%

Current Drawdown

Current decline from peak

-98.69%

-90.48%

-8.21%

Average Drawdown

Average peak-to-trough decline

-75.25%

-49.18%

-26.07%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.48%

17.27%

+2.21%

Volatility

KPTI vs. ENTA - Volatility Comparison

Karyopharm Therapeutics Inc. (KPTI) has a higher volatility of 25.00% compared to Enanta Pharmaceuticals, Inc. (ENTA) at 12.41%. This indicates that KPTI's price experiences larger fluctuations and is considered to be riskier than ENTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


KPTIENTADifference

Volatility (1M)

Calculated over the trailing 1-month period

25.00%

12.41%

+12.59%

Volatility (6M)

Calculated over the trailing 6-month period

62.82%

34.47%

+28.35%

Volatility (1Y)

Calculated over the trailing 1-year period

94.08%

110.40%

-16.32%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

94.90%

73.27%

+21.63%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

86.49%

60.65%

+25.84%

Dividends

KPTI vs. ENTA - Dividend Comparison

Neither KPTI nor ENTA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

KPTI vs. ENTA - Financials Comparison

This section allows you to compare key financial metrics between Karyopharm Therapeutics Inc. and Enanta Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


20.00M40.00M60.00M80.00M100.00M120.00M20222023202420252026
35.07M
17.16M
(KPTI) Total Revenue
(ENTA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


KPTI and ENTA have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

KPTI has higher volatility (25.00%) compared to ENTA (12.41%). In terms of maximum drawdown, KPTI dropped -99.50% vs ENTA's -96.63%.

KPTI currently has the higher Sharpe Ratio (1.33 vs 0.83), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for KPTI and ENTA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer